One case of clinical and literature case analysis on tirofiban-induced thrombocytopenia

doi:10.19803/j.1672-8629.20210664

Abstract

Abstract: Objective To explore the clinical characteristics of tirofiban-induced thrombocytopenia. Methods The diagnosis and treatment of a patient with thrombocytopenia induced by tirofiban were reported. The main clinical data of the case and relevant cases collected from PubMed, Sinomed, CNKI, and Wanfang database (as of 26 January, 2021) were summarized and analyzed. Results An acute ischemic stroke patient receiving thrombolysis combined with tirofiban was reported six hours after the application of tirofiban, the routine blood test showed thrombocytopenia. Tirofiban was discontinued and the platelet count returned to the normal range on the fourth day. A total of 13 patients were enrolled in the analysis, including 10 males and 3 females, with an average age of 60.4±12.4 years. There were 11 cases of acute coronary syndrome and 2 cases of acute ischemic stroke. 1 patient received intravenous recombinant tissue plasminogen activator combined with tirofiban, 2 patients were treated with tirofiban alone and 10 were treated with tirofiban combined with other antithrombotic drugs. The median time from the application of tirofiban to onset of thrombocytopenia was 6.0 (2.5, 22.3) hours. All the patients were defined as severe thrombocytopenia. After the onset of thrombocytopenia, tirofiban was discontinued in all the 13 patients. Of them, 1 case was improved with intravenous platelet transfusion, 2 cases received human immunoglobulin combined with platelet transfusion. With drug discontinuation, the platelet count returned to the normal range in about 5 days. Conclusion tirofiban‐related thrombocytopenia may occur in 6 hours after the first medication, which could be improved by drug withdrawal alone or combination with symptomatic treatments as appropriate.

Key words: tirofiban, thrombocytopenia, drug‐related side effects, adverse drug reaction

CLC Number:

R994.11
R972

WANG Yuan, WANG Pingping, GUO Guili, FENG Yingnan, MA Qingfeng. One case of clinical and literature case analysis on tirofiban-induced thrombocytopenia[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1140-1144.

References

[1] YANG M, HUO X, MIAO Z, et al.Platelet Glycoprotein IIb/IIIa receptor inhibitor tirofiban in acute ischemic stroke[J]. Drugs, 2019, 79(5): 515-529.
[2] WILLIAMSON DR, ALBERT M, HEELS-ANSDELL D, et al.Thrombocytopenia in critically ill patients receiving thromboprophylaxis:frequency, risk factors, and outcomes[J]. Chest, 2013, 144(4): 1207-1215.
[3] TONG W,WANG F,ZHENG ZF.Allergic reaction and thrombocytopenia syndrome induced by tirofiban: one case report[J].CGP(中国全科医学), 2016,19(S1): 470-471.
[4] ABRAMS CS, CINES DB.Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors[J]. Curr Hematol Rep, 2004, 3(2): 143-147.
[5] YE WD, XU DQ, WANG X, et al.A case report of tirofiban induced acute thrombocytopenia[J]. J Logistics University of PAPF (Medical Sciences)(武警后勤学院学报医学版), 2015, 3(24): 218-219.
[6] YU XJ, DING XM.A case report of severe tirofiban-induced thrombocytopenia[J]. Anhui Medical and Pharmaceutical Journal(安徽医药), 2013, 1(17): 170.
[7] QIU JW, LI JM, Luo T.Three cases of tirofiban-induced thrombo-cytopenia[J]. Clinical Misdiagnosis & Mistherapy(临床误诊误治), 2017, 11(30): 39-42.
[8] HOU SX, LU YM.A case of tirofiban-induced thrombocytopenia[J].Journal of Clinical Cardiology(临床心血管病杂志), 2015, 8(31): 909-912.
[9] BIAN QW, TAN Q, SUN LM, et al.Application of throm belastogram and platelet parameter monitoring in one patient with acute profound thrombocytopenia induced by tiroifban[J]. Chin J Cardiovasc Med(中国心血管杂志), 2013, 4(18): 300-302.
[10] LU AF, WANG HL, LI ZY, et al.A case report of severe tirofiban-induced acute thrombocytopenia[J]. Drugs and Clinical(中国药物经济学), 2016, 11(2): 56-58.
[11] BAI J, ZHANG JY, SHEN DL, et al.A case report of tirofiban-induced thrombocytopenia and lecture review. Chinese Journal of Practical Medicine(中国实用医刊), 2017, 18(44): 124-126.
[12] ZHANG T, KANG L, NIU YH, et al.A case pf platelet glycoprotein IIb/IIIa inhibitors- tirofiban induced severe thrombocytopenia[J]. South China Journal of CardiovascuLar Diseases(岭南心血管病杂志), 2013, 5(19): 632-636.
[13] BOSCO A, KIDSON-GERBER G, DUNKLEY S.Delayed tirofiban-induced thrombocytopenia: two case reports[J]. J Thromb Haemost, 2005, 3(5): 1109-1110.
[14] REN CL FU QZ SHI J. Thrombocytopenia caused by tirofiban in a patient with acute ischemic stroke[J]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease(实用心脑肺血管病杂志),2019, 27(12): 114-116.
[15] SIEBLER M, HENNERICI MG, SCHNEIDER D, et al.Safety of tirofiban in acute ischemic stroke: the SaTIS trial[J]. Stroke, 2011, 42(9): 2388-2392.
[16] TORGANO G, ZECCA B, MONZANI V, et al.Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial[J]. Cerebrovascular Diseases, 2010, 29(3): 275-281.
[17] Chinese Stroke Association, Chinese interventional neuroradiology society, intervention group of committee of stroke prevention and control of chinese preventive medicine association. Expert consensus on the clinical application of tirofiban in atherosclerotic cerebrovascular disease[J]. Chin J Stroke(中国卒中杂志), 2019, 10(14): 1034-1044.
[18] WU C, SUN C, WANG L, et al.Low-dose tirofiban treatment improves neurological deterioration outcome after intravenous thrombolysis[J]. Stroke, 2019, 50(12): 3481-3487.
[19] LIU J, SHI Q, SUN Y, et al.Efficacy of tirofiban administered at different time points after intravenous thrombolytic therapy with alteplase in patients with acute ischemic stroke[J]. J Stroke Cerebrovasc Dis, 2019, 28(4): 1126-1132.
[20] RAWALA MS, AHMED AS, POSINA K, et al.Tirofiban induced thrombocytopenia: a rare but severe adverse effect[J]. J Community Hosp Intern Med Perspect, 2020, 10(2): 171-173.
[21] PATTI R, SINHA A, RODRIGUEZ D, et al.Severe thrombocytopenia due to intravenous tirofiban therapy[J]. Am J Ther, 2019, 26(4): e534-e537.
[22] BAKCHOUL T, MARINI I.Drug-associated thrombocytopenia[J].Hematology Am Soc Hematol Educ Program, 2018, 2018(1): 576-583.
[23] ASTER RH, BOUGIE DW.Drug-induced immune thrombocytopenia[J]. N Engl J Med, 2007, 357(6): 580-587.
[24] BOUGIE DW, WILKER PR, WUITSCHICK ED, et al.Acute thrombo-cytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa[J]. Blood, 2002, 100(6): 2071-2076.
[25] VAYNE C, GUERY EA, ROLLIN J, et al.Pathophysiology and diagnosis of drug-Induced immune thrombocytopenia[J]. J Clin Med, 2020, 9(7): 2212.
[26] Chinese expert consensus on platelet glycoprotein IIb/IIIa receptor antagonists in the treatment of coronary atherosclerotic heart disease (2016) expert group. Chinese expert consensus on platelet glycoprotein IIb/IIIa receptor antagonists in the treatment of coronary atherosclerotic heart disease (2016)[J]. Journal of Cardiovascular & Pulmonary Disease(心肺血管病杂志), 2016, 12(35): 923-932.
[27] MULOT A, MOULIN F, FOHLEN-WALTER A, et al.Practical approach to the diagnosis and management of thrombocytopenia associated with tirofiban treatment[J]. Am J Hematol, 2004, 77(1): 67-71.
[28] QIU JW, LU B, LI JM, et al.Clinical analysis of tirofiban induced thrombocytopenia[J]. Chin J Evid Based Cardiovasc Med(中国循证心血管医学杂志), 2019, 11(1): 105-109.